AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15170544 — intervention group
Group type: EXPERIMENTAL
Intervention: Division of the pulmonary ligament
Number of subjects: 35
Study 15170544 — intervention group
Group type: COMPARATOR
Intervention: Preservation of the pulmonary ligament
Number of subjects: 35
Study 11641361 — intervention group
Group type: COMPARATOR
Intervention: Technegas inhalation during tidal breathing
Number of subjects: 11
Study 11641361 — intervention group
Group type: COMPARATOR
Intervention: Inhaled methacholine (dose sufficient to abolish expiratory flow reserve)
Number of subjects: 11
Study 11641361 — intervention group
Group type: COMPARATOR
Intervention: Three increasing doses of methacholine
Number of subjects: 11
Study 9689551 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin-dependent diabetes mellitus patients with microalbuminuria
Number of subjects: 132
Study 9689551 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 132
Study 9689551 — intervention group
Group type: COMPARATOR
Intervention: Normoalbuminuric diabetics
Number of subjects: 132
Study 7737258 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex (ICI 176,334) 50 mg/day
Number of subjects: 267
Study 7737258 — intervention group
Group type: COMPARATOR
Intervention: Castration (either medical or surgical)
Number of subjects: 267
Study 7737258 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex (100 and 150 mg/day)
Number of subjects: 267
Study 7737258 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex (50 mg/day)
Number of subjects: 267
Study 2512366 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 77092
Study 2512366 — intervention group
Group type: COMPARATOR
Intervention: Not invited to screening (control)
Number of subjects: 77092
Study 134897 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol 400 mg daily
Number of subjects: 162
Study 134897 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 162
Study 30673056 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatization tendencies (ST) in adolescents
Number of subjects: 11153
Study 30673056 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic symptoms score (SSS)
Number of subjects: 11153
Study 30673056 — intervention group
Group type: EXPERIMENTAL
Intervention: Family medical history, anxiety and depression scores, superstitious beliefs, left‐behind adolescents, teacher‐student support, family conflict, family independence and achievement orientation
Number of subjects: 11153
Study 30673056 — intervention group
Group type: EXPERIMENTAL
Intervention: Family medical history
Number of subjects: 11153
Study 30673056 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender, age, and dwelling differences
Number of subjects: 11153
Study 28603225 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 55
Study 28603225 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat
Number of subjects: 55
Study 28603225 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 55
Study 25828671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital predictors of death or cardiovascular complications during hospitalisation
Number of subjects: 1600
Study 25828671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital predictors of all-cause death during one year of follow-up
Number of subjects: 1600
Study 23512255 — intervention group
Group type: EXPERIMENTAL
Intervention: New design implant
Number of subjects: 212
Study 23512255 — intervention group
Group type: COMPARATOR
Intervention: Traditional implant
Number of subjects: 212
Study 20962502 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 64
Study 20962502 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 64
Study 20962502 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 64
Study 18086024 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenge with L. reuteri ATCC 55730/L. reuteri ATCC PTA 5289 (1.1 x 10(8) CFU) once daily for 10 days
Number of subjects: 20
Study 18086024 — intervention group
Group type: COMPARATOR
Intervention: Placebo medical devices without bacteria
Number of subjects: 20
Study 16615716 — intervention group
Group type: COMPARATOR
Intervention: Merely Recognized (MR) vs. Unrecognized (UR)
Number of subjects: 0
Study 16615716 — intervention group
Group type: COMPARATOR
Intervention: Recognized with Knowledge (RK) vs. Unrecognized (UR)
Number of subjects: 0
Study 16615716 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender Comparison
Number of subjects: 0
Study 14631217 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck anastomosis
Number of subjects: 83
Study 14631217 — intervention group
Group type: COMPARATOR
Intervention: Chest anastomosis
Number of subjects: 83
Study 10939996 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical opinion leaders
Number of subjects: 0
Study 10939996 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline implementation programs
Number of subjects: 0
Study 9093740 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention during the last 30 minutes of surgery and the first hour in PACU
Number of subjects: 0
Study 9093740 — intervention group
Group type: COMPARATOR
Intervention: Control group with identical surgical procedures and anesthesia protocol without music
Number of subjects: 0
Study 8462010 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidoxorubicin 60 mg/m2 (group A)
Number of subjects: 50
Study 8462010 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidoxorubicin 120 mg/m2 (group B)
Number of subjects: 50
Study 2941697 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoterol administered after ipratropium bromide
Number of subjects: 18
Study 2941697 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide administered before phenoterol
Number of subjects: 18
Study 31671251 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 1:100,000 epinephrine
Number of subjects: 40
Study 31671251 — intervention group
Group type: COMPARATOR
Intervention: Saline infiltration
Number of subjects: 40
Study 29891834 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose tacrolimus (4.51±1.62 ng/mL)
Number of subjects: 345
Study 29891834 — intervention group
Group type: COMPARATOR
Intervention: Standard tacrolimus dosage (6.75±2.82 ng/mL)
Number of subjects: 345
Study 27399077 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV DNA detected in breast milk
Number of subjects: 83
Study 27399077 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV DNA levels in SCM and possible SCM
Number of subjects: 83
Study 27399077 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV DNA level >200 copies/mL
Number of subjects: 83
Study 27399077 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher EBV replication in SCM
Number of subjects: 83
Study 24504441 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 0
Study 24504441 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 21999492 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed Nd:YAG laser
Number of subjects: 50
Study 21999492 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL)
Number of subjects: 50
Study 20706732 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (300 unilateral, maximal, isokinetic, eccentric contractions at 30° s(‐1))
Number of subjects: 6
Study 20706732 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (Ecc)
Number of subjects: 6
Study 20706732 — intervention group
Group type: COMPARATOR
Intervention: Concentric action (Con)
Number of subjects: 6
Study 18797304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lag-2 sparing (T2 followed by a third target)
Number of subjects: 0
Study 18797304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lag-1 sparing (T2 appears directly after T1)
Number of subjects: 0
Study 18797304 — intervention group
Group type: EXPERIMENTAL
Intervention: P3 component of event-related potential
Number of subjects: 0
Study 16189173 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml 5% glucose solution infused over 30 min after achieving hypoglycemia
Number of subjects: 16
Study 16189173 — intervention group
Group type: COMPARATOR
Intervention: 500 ml isotonic saline infused over 30 min after achieving hypoglycemia
Number of subjects: 16
Study 12651646 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB)
Number of subjects: 50
Study 12651646 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 50
Study 10657578 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG‐CoA reductase inhibitors in FH patients
Number of subjects: 23
Study 10657578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrates in HTG patients
Number of subjects: 23
Study 10657578 — intervention group
Group type: COMPARATOR
Intervention: Normolipidemic controls
Number of subjects: 23
Study 8866634 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine 75 mg
Number of subjects: 24
Study 1593512 — intervention group
Group type: EXPERIMENTAL
Intervention: Friend present‐touch (FT)
Number of subjects: 60
Study 1593512 — intervention group
Group type: EXPERIMENTAL
Intervention: Friend present‐no touch (FNT)
Number of subjects: 60
Study 1593512 — intervention group
Group type: COMPARATOR
Intervention: Stranger present‐touch (ST)
Number of subjects: 60
Study 1593512 — intervention group
Group type: COMPARATOR
Intervention: Stranger present‐no touch (SNT)
Number of subjects: 60
Study 1593512 — intervention group
Group type: COMPARATOR
Intervention: Alone (A)
Number of subjects: 60
Study 6741679 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine cigarettes (2.5 mg)
Number of subjects: 0
Study 6741679 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium nicotine cigarettes (1.5 mg)
Number of subjects: 0
Study 6741679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nicotine cigarettes (0.5 mg)
Number of subjects: 0
Study 6741679 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition with olfactory stimuli
Number of subjects: 0
Study 6741679 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition with blocked olfaction
Number of subjects: 0
Study 30659074 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically increased A1C
Number of subjects: 159940
Study 30659074 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher A1C using glycemic variants
Number of subjects: 159940
Study 30659074 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher A1C using erythrocytic variants
Number of subjects: 159940
Study 30659074 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically decreased Hb
Number of subjects: 159940
Study 29923286 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06291874 (30 mg once daily)
Number of subjects: 206
Study 29923286 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06291874 (60 mg once daily)
Number of subjects: 206
Study 29923286 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06291874 (100 mg once daily)
Number of subjects: 206
Study 29923286 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06291874 (30, 60, or 100 mg once daily)
Number of subjects: 206
Study 29923286 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06291874
Number of subjects: 206
Study 29923286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 27661415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 5mg twice a day
Number of subjects: 32
Study 27661415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 27661415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 32
Study 24264372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (cumulative dose, 13.5 mg)
Number of subjects: 30
Study 24264372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24264372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 30
Study 22398753 — intervention group
Group type: EXPERIMENTAL
Intervention: Spread containing bioactive milk peptides IPP and VPP, and plant sterols (20 g day⁻¹ for 10 weeks)
Number of subjects: 104
Study 22398753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 19815048 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (Ginko T.D. Tolidaru, Iran) at a dose of 80‐120 mg/day depending on weight (80 mg/day for <30 kg and 120 mg/day for >30 kg)
Number of subjects: 50
Study 19815048 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate at a dose of 20‐30 mg/day depending on weight (20 mg/day for <30 kg and 30 mg/day for >30 kg)
Number of subjects: 50
Study 17506152 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent pain
Number of subjects: 397
Study 15642027 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdenture supported by two IMZ implants (group A)
Number of subjects: 60
Study 15642027 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdenture supported by four IMZ implants (group B)
Number of subjects: 60
Study 15642027 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 60
Study 11920996 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular images
Number of subjects: 0
Study 11920996 — intervention group
Group type: COMPARATOR
Intervention: Neutral advertisements
Number of subjects: 0
Study 9863280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pityrosporum found in extracted follicular material
Number of subjects: 30
Study 9863280 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteria found in extracted follicular material
Number of subjects: 30
Study 9863280 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic examination of biopsied specimens
Number of subjects: 30
Study 9863280 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial culture
Number of subjects: 30
Study 7605755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve stimulator technique
Number of subjects: 40
Study 7605755 — intervention group
Group type: COMPARATOR
Intervention: Fan technique
Number of subjects: 40
Study 10109801 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol instrument
Number of subjects: 0
Study 10109801 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale
Number of subjects: 0
Study 378574 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin-trimethoprim combination (450 mg plus 120 mg twice daily)
Number of subjects: 146
Study 378574 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin alone (450 mg twice daily)
Number of subjects: 146
Study 378574 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin-trimethoprim combination and rifampicin alone
Number of subjects: 146
Study 30906562 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Nilotinib
Number of subjects: 75
Study 30906562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 28323799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (PO)
Number of subjects: 0
Study 28323799 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics (IV)
Number of subjects: 0
Study 25539239 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 min-FA30
Number of subjects: 116
Study 25539239 — intervention group
Group type: COMPARATOR
Intervention: 20 min-FA10
Number of subjects: 116
Study 23928716 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation initiated at 6 weeks after surgery
Number of subjects: 82
Study 23928716 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation initiated at 12 weeks after surgery
Number of subjects: 82
Study 21669016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal steroid plus per-oral vitamins A, C and E and selenium
Number of subjects: 34
Study 21669016 — intervention group
Group type: COMPARATOR
Intervention: Intranasal steroid
Number of subjects: 34
Study 19155904 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day nitrofurantoin regimen (100 mg capsules, taken twice daily for 1 day)
Number of subjects: 778
Study 19155904 — intervention group
Group type: COMPARATOR
Intervention: 7-day nitrofurantoin regimen (100 mg capsules, taken twice daily for 7 days)
Number of subjects: 778
Study 19155904 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day nitrofurantoin regimen
Number of subjects: 778
Study 16716870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziconotide (0.1 microg/hour starting dose, titrated to a mean dose of 0.29 microg/hour)
Number of subjects: 220
Study 16716870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 16716870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziconotide
Number of subjects: 220
Study 14757690 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 96
Study 14757690 — intervention group
Group type: COMPARATOR
Intervention: no abciximab
Number of subjects: 96
Study 11571009 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical feedback vignette with viral load decrease
Number of subjects: 207
Study 11571009 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical feedback vignette with viral load increase
Number of subjects: 207
Study 11571009 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical feedback vignette with no change in viral load
Number of subjects: 207
Study 11571009 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical feedback vignette with medication change recommended
Number of subjects: 207
Study 11571009 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical feedback vignette with no medication change recommended
Number of subjects: 207
Study 9713464 — intervention group
Group type: EXPERIMENTAL
Intervention: GRA 1 mg + DEX 20 mg
Number of subjects: 198
Study 9713464 — intervention group
Group type: EXPERIMENTAL
Intervention: GRA 3 mg + DEX 20 mg
Number of subjects: 198
Study 7871376 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath test after magnesium application
Number of subjects: 10
Study 7871376 — intervention group
Group type: COMPARATOR
Intervention: Intubation test
Number of subjects: 10
Study 3259413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (H2 antagonist)
Number of subjects: 40
Study 3259413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31434809 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks, up to 150 mg every 2 weeks)
Number of subjects: 206
Study 31434809 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC; atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day)
Number of subjects: 206
Study 31434809 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 206
Study 31434809 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 206
Study 27235022 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet (PD)
Number of subjects: 32
Study 27235022 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet with supervised exercise (PD-EX)
Number of subjects: 32
Study 26267590 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl 10 mg
Number of subjects: 28
Study 26267590 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl 20 mg
Number of subjects: 28
Study 26267590 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl 30 mg
Number of subjects: 28
Study 26267590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 24331714 — intervention group
Group type: EXPERIMENTAL
Intervention: Early food supplementation
Number of subjects: 0
Study 24331714 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplements (MMS)
Number of subjects: 0
Study 24331714 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF) counseling
Number of subjects: 0
Study 24331714 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy interventions and breastfeeding counseling
Number of subjects: 0
Study 21222064 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (2.5 mg daily)
Number of subjects: 90
Study 21222064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg daily)
Number of subjects: 90
Study 19695386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) 50 to 200 microg
Number of subjects: 111
Study 19695386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 16533286 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day-old PCT platelets
Number of subjects: 20
Study 16533286 — intervention group
Group type: COMPARATOR
Intervention: Reference (R) platelets
Number of subjects: 20
Study 15479678 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 3350 (Transipeg: polyethylene glycol with electrolytes)
Number of subjects: 100
Study 15479678 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 100
Study 15479678 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 3350
Number of subjects: 100
Study 11903155 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledermatology (store-and-forward)
Number of subjects: 49
Study 11903155 — intervention group
Group type: COMPARATOR
Intervention: General practitioner face-to-face diagnoses
Number of subjects: 49
Study 9626916 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day (tid)
Number of subjects: 676
Study 9626916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study 9626916 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (all doses)
Number of subjects: 676
Study 7946366 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 20
Study 7946366 — intervention group
Group type: COMPARATOR
Intervention: Reflective insulation
Number of subjects: 20
Study 3299174 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly nonstress testing (NST)
Number of subjects: 243
Study 3299174 — intervention group
Group type: EXPERIMENTAL
Intervention: NST plus weekly ultrasound evaluation
Number of subjects: 243
Study 3299174 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal patients)
Number of subjects: 243
Study 3299174 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring
Number of subjects: 243
Study 3299174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound plus electronic monitoring
Number of subjects: 243